A health economic analysis of Amgen's cholesterol drug Repatha found it cost-effective for high-risk adults who have never had a heart attack or stroke, coming in about 36% below a benchmark used by the American College of Cardiology and American Heart Association, according to results Amgen announced Nov. 9 at the AHA's Scientific Sessions.
Amgen described the analysis as independent and said it was led by the Duke Clinical Research Institute in collaboration with the TIMI Study Group at Mass General Brigham and Harvard. It used individual patient data from the VESALIUS-CV trial, which Amgen sponsored.